Literature DB >> 33650184

Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S.

Marco Paciotti1,2, Andrew L Schmidt3, Praful Ravi3, Rana R McKay4, Quoc-Dien Trinh1, Toni K Choueiri3.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33650184      PMCID： PMC8100555          DOI： 10.1002/onco.13736

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  5 in total

1.  Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities.

Authors:  Ariel E Marciscano; Adriana Haimovitz-Friedman; Percy Lee; Phuoc T Tran; Wolfgang A Tomé; Chandan Guha; Feng-Ming Spring Kong; Arjun Sahgal; Issam El Naqa; Andreas Rimner; Lawrence B Marks; Silvia C Formenti; Theodore L DeWeese
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-03-02       Impact factor: 7.038

Review 2.  Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review.

Authors:  Gargi Kothari; Farshad Foroudi; Suki Gill; Niall M Corcoran; Shankar Siva
Journal:  Acta Oncol       Date:  2014-08-20       Impact factor: 4.089

3.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

4.  Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Authors:  Arnaud Méjean; Alain Ravaud; Simon Thezenas; Sandra Colas; Jean-Baptiste Beauval; Karim Bensalah; Lionnel Geoffrois; Antoine Thiery-Vuillemin; Luc Cormier; Hervé Lang; Laurent Guy; Gwenaelle Gravis; Frederic Rolland; Claude Linassier; Eric Lechevallier; Christian Beisland; Michael Aitchison; Stephane Oudard; Jean-Jacques Patard; Christine Theodore; Christine Chevreau; Brigitte Laguerre; Jacques Hubert; Marine Gross-Goupil; Jean-Christophe Bernhard; Laurence Albiges; Marc-Olivier Timsit; Thierry Lebret; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

5.  Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Authors:  Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777
  5 in total
  2 in total

1.  Trend in Stereotactic Radiation Therapy Use for Management of Bone and Brain Metastases in Patients with Renal Cell Carcinoma in Australia.

Authors:  Wee Loon Ong; Shankar Siva; Roger L Milne; Farshad Foroudi; Jeremy L Millar
Journal:  Oncologist       Date:  2021-04-28

2.  Identification of a Somatic Mutation-Derived Long Non-Coding RNA Signatures of Genomic Instability in Renal Cell Carcinoma.

Authors:  Xisheng Fang; Xia Liu; Lin Lu; Guolong Liu
Journal:  Front Oncol       Date:  2021-10-05       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.